Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2021-09-29 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details about the lost share certificates and shareholders. There is no financial data, earnings information, or report attached or referenced as being published. The content is an official notification about a specific event related to share certificates, which fits best under regulatory announcements. It does not fit into categories like Annual Report, Earnings Release, or Share Issue. Given the nature and length of the document, it is best classified as a Regulatory Filing (RNS).
2021-09-29 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing about AstraZeneca Pharma India Limited receiving Import and Market Permission (Form CT-20) from the Drugs Controller General of India for a pharmaceutical product. The content is an announcement of a regulatory approval related to product launch, not a financial report, earnings release, or management discussion. The document length is short (1508 characters) and it is an announcement rather than a detailed report. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-09-26 English
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsule. ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) informing them that AstraZeneca Pharma India Limited has received Import and Market Permission (Form CT-20) from the Drugs Controller General of India for a pharmaceutical product (Selumetinib capsules). The content is an announcement of a regulatory approval related to product launch, not a financial report, earnings release, or management discussion. The document is short (1508 characters) and serves as an official regulatory announcement to the exchanges. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-09-26 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window in compliance with insider trading regulations. It mentions the trading window closure period related to the upcoming declaration of unaudited financial results but does not contain any financial data or results itself. The document is short (1237 characters) and serves as an announcement rather than a report. It is not a financial report, earnings release, or management discussion. The content fits best under a regulatory announcement category related to compliance and trading restrictions, which aligns with Regulatory Filings (RNS).
2021-09-16 English
This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing ....
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the closure of the trading window in compliance with insider trading regulations. It references the upcoming declaration of unaudited financial results but does not contain any financial data or detailed report content. The document is essentially an announcement related to trading restrictions rather than a financial report or earnings release. Given its brevity (1237 characters) and nature as a regulatory compliance notice, it fits best under Regulatory Filings (RNS).
2021-09-16 English
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform that at the Company's 42nd Annual General Meeting held on August ....
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges reporting the outcome of the Annual General Meeting (AGM) held on August 9, 2021. It specifically announces the re-appointment of Ms. Revathy Ashok as an Independent Director for a second term of 5 years. The letter references compliance with SEBI regulations and includes a brief profile of the director. There is no financial data, earnings information, or detailed report content. The document is an announcement of a board/management change resulting from the AGM, not the AGM materials themselves or the full annual report. Therefore, it fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is a formal announcement of a management appointment, not a report or presentation.
2021-08-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.